Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 55Neoplasms 15Sarcoma 12Neoplasm Metastasis 8Carcinoma, Non-Small-Cell Lung 6Triple Negative Breast Neoplasms 5Unspecified Adult Solid Tumor, Protocol Specific 3Prostatic Neoplasms 3Ovarian Neoplasms 3Sarcoma, Ewing 2Rhabdomyosarcoma 2Liposarcoma 2Leiomyosarcoma 2Carcinoma 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumors 1Salivary Gland Neoplasms 1Relapsed Solid Tumors 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Osteosarcoma 1Neurotoxicity Syndromes 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Lymphoma 1

Interventions

Ifosfamide 17Methotrexate 16Doxorubicin 14Filgrastim 13Etoposide 12Cisplatin 12Cyclophosphamide 10Gemcitabine 9Leucovorin 8Sirolimus 6Carboplatin 6Topotecan 5Irinotecan 5Granulocyte Colony-Stimulating Factor 5Temozolomide 4Sorafenib 4Radiotherapy 4Peripheral Blood Stem Cell Transplantation 4Docetaxel 4trimetrexate glucuronate 3temsirolimus 3dinutuximab 3cixutumumab 3apatinib 3Vincristine 3Specimen Handling 3Oxaliplatin 3Nivolumab 3Magnetic Resonance Spectroscopy 3Imatinib Mesylate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Osteosarcoma × eribulin × Clear all
NCT02097238 2020-05-19

Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma

National Cancer Institute (NCI)

Phase 2 Completed
19 enrolled 12 charts
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡